

Shared Care Guideline for the use of *Dornase Alfa (Pulmozyme)* for *Cystic Fibrosis* patients.

Section 1: Agreement for transfer of prescribing to GP

Patient details/addressograph

Name.....

Address.....

DOB..... Hospital no.....

Drug name and dose:...Dornase Alfa 2.5mg nebuliser solution.....

Desired clinical outcome as agreed with the patient/carer

.....

<p>Consultant</p> <p>Address:..... </p> <p>Contact no:.....</p>
<p>GP</p> <p>Address:..... </p> <p>Contact no:.....</p>

Agreement to shared care, to be signed by GP and Consultant before transfer of care to GP

Consultant signature:

Date:.....

GP signature:

Date:.....

In case of emergency contact *Name:*.....

Contact number:.....

**Shared Care Guideline for the use of *Dornase Alfa (Pulmozyme)* in
Cystic Fibrosis patients**

Responsibilities of the Consultant

- Assessing suitability of patients for treatment
- Initiating and supplying treatment until the patient is stable
- Training of patients/carer in the use of the nebuliser system
- Providing and maintaining a suitable nebuliser and compressor
- Promoting patient compliance
- Providing information for GPs
- Liaison with GPs to agree to share patients care
- Assessing and monitoring the patients response to treatment
- Reporting any adverse events to the CSM

Responsibilities of the GP

- Prescribing of nebulised dornase alfa once patients are stable
- Ensuring the patient continues to attend respiratory review clinics at the hospital
- Liaison with the consultant regarding any complications of treatment

Shared Care Guideline for the use of *Dornase Alfa (Pulmozyme)* in *Cystic Fibrosis* patients

Section 2: Information

Licensed indications

Daily administration of dornase alfa to improve pulmonary function is indicated in the management of CF patients with a forced vital capacity (FVC) greater than 40 % of predicted and over 5 years of age.

Dose and Administration

- In children five years of age and over the recommended dose is 2.5mg (one ampoule) dornase alfa nebulised once daily
- The complete contents of a single ampoule should be placed in the chamber of a jet nebuliser and nebulised to dryness once daily
- Patients will self-administer dornase alfa at home at a time relative to physiotherapy
- A suitable nebuliser and compressor is provided and maintained at Frimley Park Hospital.
- Dornase alfa should not be mixed with other drugs or solutions in the nebuliser.
- After each use the nebuliser should be dismantled and cleaned by washing with a mild detergent solution, thoroughly rinsed with tap water and allowed to air dry before re-assembly.

Cautions

- Safety of dornase alfa has not been established in pregnant women. Animal studies have shown no evidence of impaired fertility, teratogenicity or developmental defects. Advising the patient is the responsibility of the Consultant
- Extent of excretion into breast milk is unknown. However, minimal systemic absorption of dornase alfa does occur. Advising the patient is the responsibility of the Consultant

Contra-indications

Dornase alfa should not be administered to patients with a known hypersensitivity to the drug or its constituents.

Side effects

- Vocal Effects: Those frequently seen include pharyngitis and voice alteration (hoarseness). Laryngitis has been reported.
- Pulmonary Function: Upon initiation of dornase alfa therapy a transient decline in pulmonary function and an increase in sputum expectoration may occur.
- Skin Reactions: Skin rashes with or without pruritus and urticaria have been reported. These are usually mild and transient in nature.
- Dornase Alfa Antibodies: The development of dornase antibodies occurs in <5% of patients treated. The clinical significance is unknown but it does not effect the improvement in pulmonary function.

Few patients have experienced adverse effects requiring permanent discontinuation.

Interactions

There are no known interactions

Duration of treatment

Long term

References

1. BNF 50 September 2005
2. SPC Pulmozyme, Roche Products Limited, June 2005

Shared care guidelines produced by: Hawra'a Ali Respiratory Pharmacist

This does not replace the SPCs, which should be read in conjunction with this guidance. Prescribers should also refer to the appropriate paragraph in the current edition of the BNF